Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 273 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MESNA Clear all
Completed Phase 2 Interventional Results available

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

NCT00027846
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
filgrastim, carboplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy, Mesna, therapeutic conventional surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
140
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 118 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

NCT02167958
View directory record Official record
Conditions
Leukemia, MDS, Myelofibrosis, Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Mesna, Total Body Irradiation, Hematopoietic stem cell infusion, Tacrolimus, Mycophenolate, G-CSF
Drug · Radiation · Other
Lead sponsor
Rafic Farah, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Patients With Retinoblastoma

NCT00002675
View directory record Official record
Conditions
Retinoblastoma
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, mesna, vincristine sulfate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2013 · Synced Oct 20, 2026, 10:12 PM EDT
Terminated Phase 1 Interventional Results available

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

NCT00278564
View directory record Official record
Conditions
MYOPATHY
Interventions
Hematopoietic stem cell transplantation, Cyclophosphamide, Mesna, ATG(rabbit), Methylprednisolone, G-CSF, Rituxan
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional

Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

NCT00002875
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, lomustine, mesna, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 22 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
36
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma

NCT00354744
View directory record Official record
Conditions
Sarcoma
Interventions
dactinomycin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, irinotecan hydrochloride, vincristine sulfate, conventional surgery, radiation therapy, filgrastim
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
143
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 118 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

NCT00137995
View directory record Official record
Conditions
Lymphoma, Large-Cell, Diffuse
Interventions
Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna, Cisplatine, Cytosine Arabinoside, Dexamethasone, Autologous Stem Cell Transplantation, BCNU, Cytarabine, Melphalan
Drug · Procedure
Lead sponsor
Lymphoma Study Association
Other
Eligibility
18 Years to 65 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Not applicable Interventional Results available

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

NCT01005745
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Surgery, Administration of Lymphodepletion, Adoptive Cell Transfer, High Dose IL-2
Procedure · Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 1 Interventional

Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia

NCT00578266
View directory record Official record
Conditions
Anemia, Aplastic
Interventions
Cyclophosphamide,Campath IH and TBI
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

NCT00432094
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma
Interventions
carboplatin, etoposide, ifosfamide, paclitaxel, thiotepa, autologous hematopoietic stem cell transplantation, Mesna, filgrastim
Drug · Procedure · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
10 Years to 69 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 20, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional Results available

Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma

NCT00072280
View directory record Official record
Conditions
Sarcoma
Interventions
dactinomycin, cyclophosphamide, etoposide, ifosfamide, vincristine sulfate, Conventional Surgery, MESNA (mercaptoethane sulfonate), Filgrastim
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 2 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
64
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Downey, California + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 20, 2026, 10:12 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Vasodilators and Anti-Oxidant Therapy in Early ATN

NCT00286403
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Fenoldopam Mesylate and/or MESNA
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

NCT00002816
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, dexamethasone, etoposide, idarubicin, ifosfamide, leucovorin calcium, mesna, pegaspargase, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy, Methotrexate
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
30
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 20, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional Results available

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

NCT00612222
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, ALVAC MART-1 Vaccine, aldesleukin, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 20, 2026, 10:12 PM EDT
Terminated Phase 1 Interventional

Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients

NCT00040651
View directory record Official record
Conditions
Scleroderma, Systemic Sclerosis
Interventions
Fludarabine, Cyclophosphamide, Thymoglobulin, Leukapheresis, Self bone marrow transplant
Drug · Procedure
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 20, 2026, 10:12 PM EDT
Active, not recruiting Phase 2 Interventional

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

NCT00338377
View directory record Official record
Conditions
Melanoma
Interventions
Dendritic Cell Immunization, Cyclophosphamide, Fludarabine, T-Cells, Interleukin-2, Mesna, Intrathecal T-Cells, Intrathecal Interleukin-2
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Recruiting Phase 2 Interventional

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

NCT06847269
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Mesna, CD19-CAR T cell Infusion
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Recruiting Phase 2 Interventional

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

NCT06345495
View directory record Official record
Conditions
Splenomegaly, Myelofibrosis
Interventions
Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam, Eltrombopag, Busulfan, Romiplostim, Fludarabine phosphate, Cyclophosphamide, Mesna, Tacrolimus
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Results available

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

NCT01731886
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Autologous peripheral blood stem cell transplant, Lenalidomide, Dexamethasone, Stem cell collection, Melphalan, G-CSF, Cyclophosphamide, Mesna
Procedure · Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 20, 2026, 10:12 PM EDT
Terminated Phase 2 Interventional Results available

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

NCT02062359
View directory record Official record
Conditions
Metastatic Cancer, Metastatic Melanoma
Interventions
Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells, Aldesleukin, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

NCT00299182
View directory record Official record
Conditions
Lymphoma
Interventions
AMG 531, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Methotrexate, Cytarabine, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 20, 2026, 10:12 PM EDT
Recruiting Phase 2 Interventional

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497
View directory record Official record
Conditions
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Interventions
Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer

NCT00006260
View directory record Official record
Conditions
Breast Cancer
Interventions
cisplatin, etoposide, ifosfamide, Mesna
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 20, 2026, 10:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

NCT02111850
View directory record Official record
Conditions
Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer
Interventions
Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL), Cyclophosphamide, Fludarabine, Aldesleukin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 20, 2026, 10:12 PM EDT